172 related articles for article (PubMed ID: 37445963)
1. A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis.
Pafiti A; Krashias G; Tzartos J; Tzartos S; Stergiou C; Gaglia E; Smoleski I; Christodoulou C; Pantzaris M; Lambrianides A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445963
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective.
Arslan B; Ayhan Arslan G; Tuncer A; Karabudak R; Sepici Dinçel A
Bosn J Basic Med Sci; 2022 Sep; 22(5):699-706. PubMed ID: 35490364
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay.
Ulndreaj A; Sohaei D; Thebault S; Pons-Belda OD; Fernandez-Uriarte A; Campbell C; Cheo D; Stengelin M; Sigal G; Freedman MS; Scarisbrick IA; Prassas I; Diamandis EP
Diagnosis (Berl); 2023 Aug; 10(3):275-280. PubMed ID: 36788117
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of CSF neurofilament light and heavy chain protein in MS.
Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
[TBL] [Abstract][Full Text] [Related]
6. Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis.
Verberk IMW; Koel-Simmelink M; Twaalfhoven H; Vrenken H; Korth C; Killestein J; Teunissen CE; Bridel C
Mult Scler Relat Disord; 2021 May; 50():102840. PubMed ID: 33626430
[TBL] [Abstract][Full Text] [Related]
7. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
[TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels.
Revendova KZ; Zeman D; Bunganic R; Karasova K; Volny O; Bar M; Kusnierova P
Mult Scler Relat Disord; 2022 Nov; 67():104177. PubMed ID: 36130459
[TBL] [Abstract][Full Text] [Related]
9. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
[TBL] [Abstract][Full Text] [Related]
10. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis.
Rajda C; Galla Z; Polyák H; Maróti Z; Babarczy K; Pukoli D; Vécsei L
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290514
[TBL] [Abstract][Full Text] [Related]
12. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.
Hendricks R; Baker D; Brumm J; Davancaze T; Harp C; Herman A; Büdingen HV; Townsend M; Fischer SK
Bioanalysis; 2019 Aug; 11(15):1405-1418. PubMed ID: 31401845
[No Abstract] [Full Text] [Related]
13. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668
[TBL] [Abstract][Full Text] [Related]
14. Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study.
Truffi M; Garofalo M; Ricciardi A; Cotta Ramusino M; Perini G; Scaranzin S; Gastaldi M; Albasini S; Costa A; Chiavetta V; Corsi F; Morasso C; Gagliardi S
Sci Rep; 2023 Mar; 13(1):4041. PubMed ID: 36899015
[TBL] [Abstract][Full Text] [Related]
15. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
[TBL] [Abstract][Full Text] [Related]
16. Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study.
Rise HH; Brune S; Chien C; Berge T; Bos SD; Andorrà M; Valdeolivas IP; Beyer MK; Sowa P; Scheel M; Brandt AU; Asseyer S; Blennow K; Pedersen ML; Zetterberg H; de Schotten MT; Cellerino M; Uccelli A; Paul F; Villoslada P; Harbo HF; Westlye LT; Høgestøl EA
Neuroimage Clin; 2022; 35():103099. PubMed ID: 35772194
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
Yeo T; Bayuangga H; Augusto-Oliveira M; Sealey M; Claridge TDW; Tanner R; Leppert D; Palace J; Kuhle J; Probert F; Anthony DC
J Neuroinflammation; 2022 Oct; 19(1):252. PubMed ID: 36210459
[TBL] [Abstract][Full Text] [Related]
18. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
19. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
[TBL] [Abstract][Full Text] [Related]
20. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
